CN104288407A - Preparation method for nasopharynx cancer chemoradiotherapy assisting skin ointment - Google Patents
Preparation method for nasopharynx cancer chemoradiotherapy assisting skin ointment Download PDFInfo
- Publication number
- CN104288407A CN104288407A CN201410608377.5A CN201410608377A CN104288407A CN 104288407 A CN104288407 A CN 104288407A CN 201410608377 A CN201410608377 A CN 201410608377A CN 104288407 A CN104288407 A CN 104288407A
- Authority
- CN
- China
- Prior art keywords
- group
- parts
- oil
- radiotherapy
- gained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 201000011216 nasopharynx carcinoma Diseases 0.000 title claims abstract description 9
- 238000011127 radiochemotherapy Methods 0.000 title abstract description 5
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 title abstract 4
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 title abstract 4
- 239000000843 powder Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000000341 volatile oil Substances 0.000 claims abstract description 8
- 239000003921 oil Substances 0.000 claims abstract description 6
- 238000005507 spraying Methods 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 24
- 241000131458 Elsholtzia Species 0.000 claims description 22
- 241000533849 Gleditsia Species 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241001522129 Pinellia Species 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 238000002512 chemotherapy Methods 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 5
- 241001289529 Fallopia multiflora Species 0.000 abstract description 3
- 241000931143 Gleditsia sinensis Species 0.000 abstract description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract description 3
- 244000001632 Acorus gramineus Species 0.000 abstract description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 2
- 241000104430 Elsholtzia rugulosa Species 0.000 abstract description 2
- 241000511970 Leycesteria formosa Species 0.000 abstract description 2
- 241000018646 Pinus brutia Species 0.000 abstract description 2
- 240000002913 Trifolium pratense Species 0.000 abstract description 2
- 235000015724 Trifolium pratense Nutrition 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 abstract 3
- 240000002381 Prunus davidiana Species 0.000 abstract 2
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract 1
- 235000011613 Pinus brutia Nutrition 0.000 abstract 1
- 240000003705 Senecio vulgaris Species 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 235000013526 red clover Nutrition 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 33
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 21
- 229960002949 fluorouracil Drugs 0.000 description 21
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 230000002147 killing effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 230000007096 poisonous effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YYCCUFKHCNSRIA-HJWRWDBZSA-N 2-[(z)-heptadec-10-enyl]-6-methoxycyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCC\C=C/CCCCCCCCCC1=CC(=O)C=C(OC)C1=O YYCCUFKHCNSRIA-HJWRWDBZSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- YYCCUFKHCNSRIA-UHFFFAOYSA-N Pallasone A Natural products CCCCCCC=CCCCCCCCCCC1=CC(=O)C=C(OC)C1=O YYCCUFKHCNSRIA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000009969 fructus bruceae Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000544682 Acorus tatarinowii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000000793 Pinus armandii Species 0.000 description 1
- 235000011612 Pinus armandii Nutrition 0.000 description 1
- 244000101284 Pinus kesiya Species 0.000 description 1
- 235000005026 Pinus kesiya Nutrition 0.000 description 1
- 240000007263 Pinus koraiensis Species 0.000 description 1
- 235000011615 Pinus koraiensis Nutrition 0.000 description 1
- 235000011609 Pinus massoniana Nutrition 0.000 description 1
- 241000018650 Pinus massoniana Species 0.000 description 1
- 235000011610 Pinus tabuliformis Nutrition 0.000 description 1
- 241000018651 Pinus tabuliformis Species 0.000 description 1
- 235000011611 Pinus yunnanensis Nutrition 0.000 description 1
- 241000018652 Pinus yunnanensis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of a nasopharynx cancer chemoradiotherapy assisting skin ointment, and aims to solve the treatment problem of nasopharynx cancer. The preparation method is characterized by comprising the following steps: (1) extracting volatile oil from groundsel, acorus gramineus and polygonum multiflorum coarse powder for later use; (2) grinding Chinese honey locust and peach gum to form fine powder for later use; (3) conducting aqueous extraction on elsholtzia rugulosa, pungent litse flower, leycesteria formosa, rhizoma pinelliae (decocted in a bag), trifolium pratense, cassia twig and the dregs obtained in the step 1, and conducting vacuum concentration and drying to obtain a primary material; (4) heating sesame oil, adding pine needles to the heated oil, filtering the oil material, adding the primary material and the Chinese honey locust and peach gum powder to the oil material at 120 DEG C, cooling, spraying the volatile oil, mixing uniformly, and subpackaging to obtain the product. The clinical experiments show that the nasopharynx cancer chemoradiotherapy assisting skin ointment is synergetic with the chemotherapy, good in in curative effect, high in safety, and worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of preparation method of nasopharyngeal carcinoma aid in skin ointment.
Background technology
The sickness rate of malignant tumor is in recent years in sustainable growth trend, and chemotherapy and operative treatment, radiotherapy are the Main Means of current oncotherapy.Maximum tolerated dose chemotherapy (maximum tolerated dose, MTD) is the principal mode of classic chemotherapy, because toxic and side effects is heavier, needs the intermission of 2 ~ 3 weeks to be beneficial to the recovery of body tissue organ dysfunction, easily produce tumor drug resistance after each cycle chemotherapy.There is multiple theory such as tumor stem cell hypothesis can explain that tumor cell is insensitive or produce recurrence and the transfer that drug resistance or resistance cause tumor over the course for the treatment of to chemicotherapy at present, it is the balance of chemicotherapy toxicity and killing action at all, for " completely " killing off tumor cells, only have increasing to put (change) and treat dosage, but, this brings again the toxic and side effects being difficult to bear to patient, cause Endodontic failure.
Therefore, clinical cancer therapy takes chemoradiation therapy hypersitization medicine to carry out auxiliary treatment more in recent years, its object is to when not increasing toxic action, maximized increase killing action, reduce tumor drug resistance incidence rate, as the xeloda activated in selectivity tumor, Selective COX-2 inhibitor celecoxib, meloxicam etc.But said medicine is expensive, and its adverse effect of life-time service is high, causes patient compliance poor.
In recent years, Chinese medicine adjuvant therapy Therapy study mainly concentrates on righting and two aspects of getting rid of evils, the former is as medicine or Chinese medicine single components such as ginsenoside, ganoderan, the Radix Astragali, Radix Angelicae Sinensis, how to start with from air making-up and spleen enlivening, supplementing QI and nourishing YIN, protection normal cell, immune organ, reduce radiotherapy and chemotherapy medicine to the infringement of body; The latter is as hard masses softening and resolving, removing blood stasis medicine or Chinese medicine single components such as Venenum Bufonis, Fructus Bruceae, irisquinone, pocket clothing polysaccharide, and how starting with from " treating the poisonous disease with poisonous drugs ", toxic and side effects is large.And in prescription, two kinds of medicines with the use of, its effect produces conflicts, and affects the treatment.
Therefore, still lack a kind of not simple Chinese medicine of starting with from " killing " or " righting " angle or formula, Combined with Radiotherapy chemotherapeutic sensitivity uses.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the preparation method of the little nasopharyngeal carcinoma aid in skin ointment of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition of chemotherapeutic sensitivity, it is characterized in that being prepared from by the crude drug of following weight proportion: play the flageolet at Elsholtzia regulosa 10 ~ 30 parts, Folium Elsholtziae cypriani 10 ~ 30 parts, night 3 ~ 10 parts, Pinellia leaven 6 ~ 9 parts, Radix Polygoni Multiflori 3 ~ 10 parts, Herba Trifolii Pratentis 6 ~ 12 parts, Herba Senecionis Scandentis 6 ~ 12 parts, 1 ~ 3 part, Fructus Gleditsia, Rhizoma Acori Graminei 6 ~ 12 parts, Ramulus Cinnamomi 1 ~ 5 part, Resina persicae 10 ~ 25 parts, 3 ~ 10 parts, Folium Pini, 50 parts, Oleum Sesami.
Chinese medicine of the present invention can be prepared from by following method:
(1) Herba Senecionis Scandentis, Rhizoma Acori Graminei, Radix Polygoni Multiflori coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting, medicinal residues are continued to employ;
(2) Fructus Gleditsia, Resina persicae are pulverized 100 mesh sieves, and become fine powder for subsequent use;
(3) Elsholtzia regulosa, Folium Elsholtziae cypriani, night are played the flageolet, Pinellia leaven (decocting a drug wrapped), Herba Trifolii Pratentis, Ramulus Cinnamomi and the mixing of step 1 gained medicinal residues add 3 times of water yields, decoct with water 2 times, each 30min, collecting decoction, leaves standstill and filters, get filtrate, concentrating under reduced pressure, spraying dry, draws just material;
(4) Oleum Sesami is heated to 160 DEG C, adds the Folium Pini of pulverizing, after 3min, oil plant is filtered, 120 DEG C time, add step 3 gained just expect and gained Fructus Gleditsia, Resina persicae fine powder in step 2, Keep agitation 5min, sprayed into by gained volatile oil in step 1 when being cooled to 60 DEG C, the subpackage that stirs forms.
Wherein said: Elsholtzia regulosa is the herb of labiate scabriculous Herba Moslae Elsholtzia rugulosa Hemsl..Acrid in the mouth; Bitter; Cool in nature.Merit can be induced sweat and be brought down a fever; Removing dampness for regulating stomach.
Folium Elsholtziae cypriani is the fragrant Elsholtzia cypriani(Pavol. of labiate weeds) leaf of C.Y.Wu et S.chow or stem and leaf.Acrid in the mouth; Cool in nature.Merit can be delivered in heat clearing away; Removing toxic substances preventing the attack (or recurrence) of malaria.
Night plays the flageolet, and for Caprifoliaceae to play the flageolet Leycesteria formosa Wall. night, is used as medicine with Herb.Nature and flavor are bitter, cool.Merit can removing blood stasis, dispels the wind, relievings asthma.
Pinellia leaven, the dry tuber powder for the aroid Rhizoma Pinelliae adds the herbal leaven that flour, Sucus Zingberis etc. are made.Bitter in the mouth is pungent, and property is put down.Merit can drying dampness to eliminate phlegm, and stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass, helps digestion long-pending, control and have loose bowels.
Radix Polygoni Multiflori, be the dried root of polygonum multiflorum thunb Polygonum multiflorum Thunb., nature and flavor are bitter, sweet, puckery, temperature.Return liver, the heart, kidney channel.Merit can nourishing the blood and yin; Removing toxic substances, eliminating carbuncle, loosening bowel to relieve constipation.
Herba Trifolii Pratentis is inflorescence and the wounded in the battle branch and leaf of leguminous plant Herba Trifolii Pratentis Trifolium pratense L..Sweet in the mouth; Bitter; Cold nature.Return lung meridian.Merit can clearing and antitussive; Mass dissipating and swelling eliminating.
Herba Senecionis Scandentis is the aerial parts of feverfew Herba Senecionis Scandentis.Cold in nature, bitter in the mouth.Merit can heat-clearing and toxic substances removing, removing obstruction for relieving pain.
Fructus Gleditsia is the fruit of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..Nature and flavor are pungent, temperature.Return lung; Large intestine channel.Merit can expelling phlegm for arresting cough; Have one's ideas straightened out to lead to and close; Parasite killing eliminating stagnation.
Rhizoma Acori Graminei is the dry rhizome of acorus gramineus araceae plant Acorus tatarinowii Schott.Nature and flavor are pungent, bitter, temperature.GUIXIN, stomach warp.Merit can be whetted the appetite in removing dampness, eliminating phlegm of having one's ideas straightened out, refreshment Fructus Alpiniae Oxyphyllae.
Ramulus Cinnamomi is the dry twig of canella Cortex Cinnamomi Cinnamomum cassia Presl.Nature and flavor acrid, sweet, warm.GUIXIN, lung, urinary bladder channel.Merit can diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.
Folium Pini is the dry needle of the Folium seu Strobilus Pini sibiricae in Pinaceae pine genus plant, Pollen pini thunbergii, Pinus tabuliformis, Pinus koraiensis, Pinus armandi Franch-P. Komavovii Lavl., pinus yunnanensis faranch, Pinus kesiya Royle ex Gordon var. langbianensis (A.Chev) Gaussen, Pinus massoniana Lamb etc.Merit can dispeiling pathogenic wind and removing dampness, killing parasites for relieving itching.
Resina persicae, for rosaceous plant peach tree does the resin of upper outflow.Merit can removing heat from blood and promoting blood circulation, benefiting qi for promoting granulation.
Oleum Sesami, the fatty oil that the mature seed milling process for Pedaliaceae plant sesame Sesamum indicum L. obtains.
Composition principle: maximum tolerated dose chemotherapy (maximum tolerated dose, MTD) is the balance of chemicotherapy toxicity and killing action at all.For " completely " killing off tumor cells, only have increasing to put (change) and treat dosage, but this brings again the toxic and side effects being difficult to bear to patient, cause Endodontic failure.In recent years, Chinese medicine adjuvant therapy Therapy study mainly concentrates on righting and two aspects of getting rid of evils, the former is as medicine or Chinese medicine single components such as ginsenoside, ganoderan, the Radix Astragali, Radix Angelicae Sinensis, how to start with from air making-up and spleen enlivening, supplementing QI and nourishing YIN, protection normal cell, immune organ, reduce radiotherapy and chemotherapy medicine to the infringement of body; The latter is as hard masses softening and resolving, removing blood stasis medicine or Chinese medicine single components such as Venenum Bufonis, Fructus Bruceae, irisquinone, pocket clothing polysaccharide, and how starting with from " treating the poisonous disease with poisonous drugs ", toxic and side effects is large.And in prescription, two kinds of medicines with the use of, its effect produces conflicts, and affects the treatment.Therefore, still lack a kind of not simple Chinese medicine of starting with from " killing " or " righting " angle or formula, Combined with Radiotherapy chemotherapeutic sensitivity uses.
Compared with prior art, the present invention has following characteristics:
1, get Elsholtzia regulosa in side, Folium Elsholtziae cypriani is monarch, Elsholtzia regulosa and Folium Elsholtziae cypriani 1:1 ratio collocation prescription become the basis of we, experiment proves that (specific experiment data are shown in specific embodiment part) Elsholtzia regulosa and Folium Elsholtziae cypriani geometric ratio decocting liquid assist 5-FU chemotherapy or adjuvant radiotherapy can obviously reduce tumor weight, improves tumour inhibiting rate.Its action pathway may be relevant to COX inhibitory action, but in experiment examination, Elsholtzia regulosa effect and dosage are clearly relevant, Elsholtzia regulosa and Folium Elsholtziae cypriani 1:2 ratio and then without above-mentioned potentiation
2, get in side and play the flageolet night, Herba Trifolii Pratentis, Herba Senecionis Scandentis, Radix Polygoni Multiflori coordinates monarch drug to start with from the poison blood, expelling wind and clearing away heat eliminating stagnation, but because night plays the flageolet, Herba Trifolii Pratentis, Herba Senecionis Scandentis drug effect is all invigorated blood circulation dynamic blood effect, under routine dose (15-30g/ day) have and promote blood vessel new role, and angiogenesis and tumor development closely bound up, so here using dosage is all improved, play the flageolet night 3 ~ 10g/ day, Herba Trifolii Pratentis 6 ~ 12g/ day, Herba Senecionis Scandentis 6 ~ 12g/ day, at this dose, namely medicine can keep the pharmacological action of former expelling wind and clearing away heat eliminating stagnation, again without the anxiety of dynamic blood,
3, get Pinellia leaven, Rhizoma Acori Graminei dampness sending down the abnormal ascending QI, eliminating phlegm of having one's ideas straightened out in side, contribute to antagonism radiotherapy and chemotherapy medicine to the damage of gastrointestinal, and the greasy side effect of taste that this two herbal medicine does not have other spleen reinforcing medicines, and Resina persicae there is nourishing to nourish blood effect;
4, medicine coordinates lifting: Fructus Gleditsia is had one's ideas straightened out to lead to and closes, the flat gas that spins of Ramulus Cinnamomi, although the medicine of the soaping agents contained in Fructus Gleditsia, single use can stimulate the secretion of gastric mucosa and reflexive promotion respiratory mucus, and then produce nauseous phlegm-dispelling functions, but coordinating the Ramulus Cinnamomi of low dose of (1 ~ 5 g/ day) to use can open entire by orderly and clearly mechanism of qi, reduce the nauseating sense of patient and gastrointestinal reaction, the warm DeGrain of Ramulus Cinnamomi under this dosage, can not cause yang-energy to cross Sheng and cause local blood circulation too fast and promote tumor growth;
5, Folium Pini, Resina persicae, Oleum Sesami contribute to medicine topical transdermal and absorb, and the viscosity of medicine, and Folium Pini can reduce medicine local excitation, prevents the generation of skin adverse reaction.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: play the flageolet at Elsholtzia regulosa 20g, Folium Elsholtziae cypriani 20g, night 6g, Pinellia leaven 9g, Radix Polygoni Multiflori 6g, Herba Trifolii Pratentis 10g, Herba Senecionis Scandentis 10g, Fructus Gleditsia 3g, Rhizoma Acori Graminei 10g, Ramulus Cinnamomi 2g, Resina persicae 20g.
The preparation method of embodiment 1 is: played the flageolet at Elsholtzia regulosa, Folium Elsholtziae cypriani, night, Pinellia leaven (decocting a drug wrapped), Radix Polygoni Multiflori, Herba Trifolii Pratentis, Herba Senecionis Scandentis, Fructus Gleditsia, Rhizoma Acori Graminei, Ramulus Cinnamomi mixing and water adding decoct, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges, being divided into two parts of morning and evenings takes, and sooner or later respectively gets odd-numbered day dosage half amount Resina persicae molten every day and takes.
Embodiment 2, crude drug weight proportion: play the flageolet at Elsholtzia regulosa 10 parts, Folium Elsholtziae cypriani 10 parts, night 3 parts, Pinellia leaven 6 parts, Radix Polygoni Multiflori 3 parts, Herba Trifolii Pratentis 6 parts, Herba Senecionis Scandentis 6 parts, 1 part, Fructus Gleditsia, Rhizoma Acori Graminei 6 parts, Ramulus Cinnamomi 1 part, Resina persicae 10 parts, 3 parts, Folium Pini, 50 parts, Oleum Sesami.
Embodiment 3, crude drug weight proportion: play the flageolet at Elsholtzia regulosa 20 parts, Folium Elsholtziae cypriani 20 parts, night 6 parts, Pinellia leaven 9 parts, Radix Polygoni Multiflori 6 parts, Herba Trifolii Pratentis 10 parts, Herba Senecionis Scandentis 10 parts, 3 parts, Fructus Gleditsia, Rhizoma Acori Graminei 10 parts, Ramulus Cinnamomi 2 parts, Resina persicae 20 parts, 9 parts, Folium Pini, 50 parts, Oleum Sesami.
Embodiment 4, crude drug weight proportion: play the flageolet at Elsholtzia regulosa 30 parts, Folium Elsholtziae cypriani 30 parts, night 10 parts, Pinellia leaven 9 parts, Radix Polygoni Multiflori 10 parts, Herba Trifolii Pratentis 12 parts, Herba Senecionis Scandentis 12 parts, 3 parts, Fructus Gleditsia, Rhizoma Acori Graminei 12 parts, Ramulus Cinnamomi 5 parts, Resina persicae 25 parts, 10 parts, Folium Pini, 50 parts, Oleum Sesami.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) Herba Senecionis Scandentis, Rhizoma Acori Graminei, Radix Polygoni Multiflori coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting, medicinal residues are continued to employ;
(2) Fructus Gleditsia, Resina persicae are pulverized 100 mesh sieves, and become fine powder for subsequent use;
(3) Elsholtzia regulosa, Folium Elsholtziae cypriani, night are played the flageolet, Pinellia leaven (decocting a drug wrapped), Herba Trifolii Pratentis, Ramulus Cinnamomi and the mixing of step 1 gained medicinal residues add 3 times of water yields, decoct with water 2 times, each 30min, collecting decoction, leaves standstill and filters, get filtrate, concentrating under reduced pressure, spraying dry, draws just material;
(4) Oleum Sesami is heated to 160 DEG C, adds the Folium Pini of pulverizing, after 3min, oil plant is filtered, 120 DEG C time, add step 3 gained just expect and gained Fructus Gleditsia, Resina persicae fine powder in step 2, Keep agitation 5min, sprayed into by gained volatile oil in step 1 when being cooled to 60 DEG C, the subpackage that stirs forms.
The efficient combination of said medicine, coordinates mutually, effectively reach the object of chemotherapeutic sensitivity, and side effect is less.Experiment and clinical data sufficient proof based on the above results, interrelated data is as follows.
One, square foundation zoopery.
1. materials and methods.
1.1 laboratory animals: Kunming mouse, body weight 20 ± 2g, male and female half and half.
1.2 tumor strain: H
22the strain of hepatic ascites tumor, is provided by institute of materia medica of Beijing Chinese Academy of Sciences.
1.3 medicine.
1.3.1 5-fluorouracil (5-FU) injection, becomes 1g/L with front normal saline dilution.
1.3.2 the preparation of Elsholtzia regulosa and Folium Elsholtziae cypriani equal proportion (1:1) proportioning medicine: take Elsholtzia regulosa and each 250g of Folium Elsholtziae cypriani, mixing and water adding decocts, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges, concentrating under reduced pressure becomes clear paste to preserve, and uses front normal saline dilution, is equivalent to 0.5g crude drug/ml after dilution.
1.3.2 the preparation of Elsholtzia regulosa and the low ratio of Folium Elsholtziae cypriani (1:2) proportioning medicine: take Elsholtzia regulosa 125g and Folium Elsholtziae cypriani 250g, mixing and water adding decocts, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges, concentrating under reduced pressure becomes clear paste to preserve, and uses front normal saline dilution, is equivalent to 0.375g crude drug/ml after dilution.
1.4 modelings, grouping and processing method.
1.4.1 modeling: aseptically extract well-grown H
22the tumor liquid of liver cancer mouse, becomes 2 × 10 with normal saline dilution
7the cell suspension of individual/ml, 0.2ml/, mouse hind leg subcutaneous vaccination.
1.4.2 chemotherapy grouping and processing method: mice was divided into 4 groups at random in the 2nd day after tumor strain is inoculated, often organizes 10, be respectively: matched group, 5-FU group, 5-FU+ equal proportion group, the low ratio group of 5-FU+.Matched group gives normal saline gavage every day, and remaining three groups give 5-FU 0.01g/kg lumbar injection, every day 1 time, continuous 3d, drug withdrawal 1d, then successive administration 2d.5-FU+ equal proportion group gives 8g(crude drug)/kg equal proportion decoction gavage, every day 1 time, continuous 15d.5-FU+ low ratio group gives 6.25g(crude drug)/kg low ratio decoction gavage, every day 1 time, continuous 15d.Put to death mice in the 16th day, get tumor and weigh, calculate tumour inhibiting rate and Increasing Efficiency.
1.4.3 radiotherapy grouping and processing method: mice was divided into 4 groups at random in the 2nd day after tumor strain is inoculated, often organizes 10.Be respectively: matched group, combination radiotherapy group, radiotherapy+equal proportion group, radiotherapy+low ratio group.Matched group gives normal saline gavage, and remaining three groups start to add radiotherapy in administration on the 7th day, basic crack 8Gy/d, every day 1 time, continuous 3d, dosage escalation, 8,9,10Gy.Radiotherapy+equal proportion group gives 8g(crude drug)/kg equal proportion decoction gavage, every day 1 time, continuous 15d.Radiotherapy+low ratio group gives 6.25g(crude drug)/kg low ratio decoction gavage, every day 1 time, continuous 15d.Put to death mice in the 16th day, get tumor and weigh, calculate tumour inhibiting rate and Increasing Efficiency.
1.5 statistical method results adopt SPSS 16.0 to carry out statistical analysis, and measurement data t checks.
2 results.
2.1 couples of H
22the potentiation of tumor-bearing mice chemotherapy.
Matched group, 5-FU group, 5-FU+ equal proportion group, the tumor of the low ratio group of 5-FU+ is heavily respectively 2.46 ± 0.78g, 1.39 ± 0.51g, 0.98 ± 0.31g, 1.25 ± 0.42g, 5-FU group, 5-FU+ equal proportion group, 5-FU+ is low, and ratio group is all obviously better than matched group, its tumour inhibiting rate is respectively 43.50%, 60.16%, 49.19%, 5-FU+ equal proportion group compares with 5-FU group, its tumor is heavy obviously to be reduced, tumour inhibiting rate obviously increases (P<0.05), and the low ratio group of 5-FU+ compares with 5-FU group, then group difference does not have statistical significance (P>0.05).Therefore, can find out that Elsholtzia regulosa and Folium Elsholtziae cypriani equal proportion (1:1) proportioning medicine are to mice H
22the 5-FU treatment of hepatocarcinoma has potentiation, and Increasing Efficiency is 29.50%.
2.2 couples of H
22the potentiation of tumor-bearing mice radiotherapy.
Matched group, combination radiotherapy group, radiotherapy+equal proportion group, the tumor of radiotherapy+low ratio group is heavily respectively 2.38 ± 0.86g, 1.44 ± 0.46g, 0.97 ± 0.38g, 1.21 ± 0.39g, combination radiotherapy group, radiotherapy+equal proportion group, radiotherapy+low ratio group is all obviously better than matched group, its tumour inhibiting rate is respectively 39.50%, 59.24%, 49.16%, radiotherapy+equal proportion group compares with combination radiotherapy group, its tumor is heavy obviously to be reduced, tumour inhibiting rate obviously increases (P<0.05), and radiotherapy+low ratio group compares with combination radiotherapy group, then group difference does not have statistical significance (P>0.05).Therefore, can find out that Elsholtzia regulosa and the low ratio of Folium Elsholtziae cypriani (1:2) proportioning medicine are to mice H
22the radiotherapy in the treatment of hepatocarcinoma has potentiation, and Increasing Efficiency is 32.64%.
Two, Clinical controlled trial.
1 object and method.
1.1 object.
1.1.1 case selection: in January, 2011 ~ 2013 are diagnosed as Nasopharyngeal Carcinoma Patients 89 example year February, all make a definite diagnosis through histopathologic examination, and Ka Shi scoring >65 divides, and before treatment, surrounding hemogram, hepatic and renal function, electrocardiogram etc. check without radiotherapy contraindication.Wherein man 61 example, female 28 example, age 26 ~ 67(42.6 ± 8.5) year.Pathological: scale cancer 78 falls, adenocarcinoma 7 example, undifferentiated carcinoma 4 example.By stages by International Union Against Cancer (UICC) staging scale in 1989: III phase 49 example, IV phase 40 example.
1.1.2 divide into groups: be divided into matched group 30 example, decoction group 30 example and ointment group 29 example.Before three groups of patient treatments sex, the age and by stages on compare, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method:
Matched group takes conventional radiotheraphy+FP scheme chemotherapy: 1. Radiation treatment plans: primary tumor first face neck combines wild DT 36Gy, after change ears before wild or wild to DT 70 ~ 74 Gy before adding nose; Metastatic Lymph Nodes first face neck combines wild DT 36 Gy, after change full neck tangent line Dm 23 Gy, then make local dose to DT 64 Gy to there being lymph node region to add electron beam; 2. FP scheme chemotherapy: 5-fluorouracil 750 mg/m
2, 1st ~ 3 days; Cisplatin 30 mg/m
2, 1 ~ 3d, in radiotherapy pre-induction 2 cycles (14d is 1 cycle);
Decoction group is on matched group scheme basis, and before chemotherapy starts, 1 thoughtful radiotherapy terminates with gained decoction oral in the embodiment of the present invention 1,2 times/d;
Ointment group, on matched group Radiation treatment plans basis, starts first 1 week with gained decoction oral in the embodiment of the present invention 1,2 times/d to radiotherapy from chemotherapy; Starting front 1 thoughtful radiotherapy from radiotherapy terminates with gained ointment in the embodiment of the present invention 3 at radiotherapy position local topical, and it is 1 time/d that radiotherapy starts medication in first 1 week, and radiation period medication is 2 times/d, and medication and radiotherapy in the treatment interval are at more than 1h;
3 groups of radiation therapy session terminate rear evaluation curative effect.
1.2.2 criterion of therapeutical effect: with reference to WHO standard evaluation curative effect in " Radiation Oncology ", be divided into CR(completed tumor regression), PR(tumor partial regression >=50%), NC(tumor regression <50%, or unchanged), PD(tumor increase >=25% or there is new focus), effective percentage=(CR+PR)/total case load.
1.2.3 1 year is followed up a case by regular visits to, record local recurrence and metastasis situation.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.Measurement data t checks, enumeration data χ
2inspection.
2 results.
2.1 3 groups of Comprehensive Clinical comparitive study: see the following form,
| Group | Number of cases | CR | PR | NC | PD | Effective percentage |
| Matched group | 30 | 2 | 9 | 12 | 7 | 36.67% |
| Decoction group | 30 | 5 | 15 | 7 | 3 | 66.67% |
| Ointment group | 29 | 3 | 16 | ,6 | 4 | 65.52% |
Decoction group effective percentage is apparently higher than matched group (χ
2=5.41, P<0.05), ointment group effective percentage is apparently higher than matched group (χ
2=4.91, P<0.05).Result shows, pharmaceutical composition disclosed in this invention has the effect of chemicotherapy potentiation, and chemotherapy adopts oral intervention, the effect that adopts ointment external to intervene before radiotherapy and in radiotherapy and omnidistance decoction oral effect suitable (P>0.05).
In 2.2 one years, local recurrence and metastasis situation compare: three groups of patient's local relapse and metastasis incidence rate situation are matched group 33.3%(10/30), 30.0%(9/30), decoction group 10.0%(3/30), 13.33%(4/30), ointment group 13.8%(4/29), 13.8%(4/29).Decoction group local relapse is starkly lower than matched group (χ
2=4.81, P<0.05).Overall recurrence and the rate of transform compare, and decoction group and ointment group are all lower than matched group (χ
2=5.71, P<0.05; χ
2=4.05, P<0.05).
2.3 radiotherapy local skin toxicity incidence rates compare: decoction group (10/30), ointment group (7/29) are all lower than matched group (18/30), and difference has statistical significance (P<0.05, P<0.01).
3. conclusion.
This result of study shows, take the oral and ointment group external effective percentage of decoction group of the present invention apparently higher than matched group, show that prescription of the present invention has good gain effect for radiotherapy, and the untoward reaction of radiotherapy local skin a situation arises is starkly lower than matched group, illustrate that pharmaceutical composition prepared by the inventive method has the advantage that untoward reaction is comparatively light, safety is higher in radiotherapy potentiation, local attenuation.
Claims (1)
1. a preparation method for nasopharyngeal carcinoma aid in skin ointment, is characterized in that, is made up of following steps:
(1) Herba Senecionis Scandentis, Rhizoma Acori Graminei, Radix Polygoni Multiflori coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting, medicinal residues are continued to employ;
(2) Fructus Gleditsia, Resina persicae are pulverized 100 mesh sieves, and become fine powder for subsequent use;
(3) Elsholtzia regulosa, Folium Elsholtziae cypriani, night are played the flageolet, Pinellia leaven (decocting a drug wrapped), Herba Trifolii Pratentis, Ramulus Cinnamomi and the mixing of step 1 gained medicinal residues add 3 times of water yields, decoct with water 2 times, each 30min, collecting decoction, leaves standstill and filters, get filtrate, concentrating under reduced pressure, spraying dry, draws just material;
(4) Oleum Sesami is heated to 160 DEG C, adds the Folium Pini of pulverizing, after 3min, oil plant is filtered, 120 DEG C time, add step 3 gained just expect and gained Fructus Gleditsia, Resina persicae fine powder in step 2, Keep agitation 5min, sprayed into by gained volatile oil in step 1 when being cooled to 60 DEG C, the subpackage that stirs forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410608377.5A CN104288407A (en) | 2014-11-04 | 2014-11-04 | Preparation method for nasopharynx cancer chemoradiotherapy assisting skin ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410608377.5A CN104288407A (en) | 2014-11-04 | 2014-11-04 | Preparation method for nasopharynx cancer chemoradiotherapy assisting skin ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104288407A true CN104288407A (en) | 2015-01-21 |
Family
ID=52308518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410608377.5A Pending CN104288407A (en) | 2014-11-04 | 2014-11-04 | Preparation method for nasopharynx cancer chemoradiotherapy assisting skin ointment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104288407A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526498A (en) * | 2012-02-21 | 2012-07-04 | 姜永华 | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof |
| CN103446261A (en) * | 2012-06-05 | 2013-12-18 | 中国医学科学院肿瘤医院 | Chinese medicinal composition used for preventing and/or treating related skin lesion in tumour treatment |
-
2014
- 2014-11-04 CN CN201410608377.5A patent/CN104288407A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526498A (en) * | 2012-02-21 | 2012-07-04 | 姜永华 | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof |
| CN103446261A (en) * | 2012-06-05 | 2013-12-18 | 中国医学科学院肿瘤医院 | Chinese medicinal composition used for preventing and/or treating related skin lesion in tumour treatment |
Non-Patent Citations (5)
| Title |
|---|
| 张诗军等: "《肿瘤中医生物养生治疗学》", 31 July 2013, 广东科技出版社 * |
| 王梅云等: ""中药配合放疗对40例鼻咽癌患者的疗效分析"", 《中外医疗》 * |
| 陶欣: ""中药在鼻咽癌放化疗中的作用"", 《中国实用医药》 * |
| 马纯政等: "《肿瘤辨证施治策略与案例》", 31 January 2012, 郑州大学出版社 * |
| 黄初冬等: ""中药与鼻咽癌放射治疗研究概述"", 《中国中西医结合杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103566350A (en) | Pharmaceutical composition having blood sugar reducing effect | |
| CN103386008A (en) | Chinese medicine composition for treating endocrine dyscrasia | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN105641419A (en) | Traditional Chinese medicine composition for treating Yin deficiency type cough caused by lung cancer | |
| CN102204978B (en) | Medicinal composition for treating cancer pain and preparation thereof | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN103239674B (en) | Antineoplastic traditional Chinese medicine composition and preparation method thereof | |
| CN113209194A (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN103566349A (en) | Medicinal composition for treating hyperglycemia and hyperlipidemia | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN109876127A (en) | A kind of blood-nourishing angelica capsules and preparation method thereof | |
| CN104225282A (en) | Traditional Chinese medicine for treating postpartum headache | |
| CN111388604B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN104288407A (en) | Preparation method for nasopharynx cancer chemoradiotherapy assisting skin ointment | |
| CN104288406A (en) | Synergetic medicinal composition for nasopharynx cancer chemoradiotherapy | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN105362999A (en) | Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof | |
| CN100571739C (en) | Herbal mixture of treatment cardiovascular disease and preparation method thereof | |
| CN105748735A (en) | Pharmaceutical composition for treating ovarian cyst and preparation method thereof | |
| CN105396105A (en) | A method of preparing a traditional Chinese medicine composition for preventing and treating recurrent common cold in children | |
| CN104288404A (en) | Assisted drug for postoperative chemo-treatment of non-small cell lung cancer | |
| CN104288405A (en) | Preparation method of assisted drug for postoperative chemo-treatment of non-small cell lung cancer | |
| CN105343688A (en) | Medicine composition for treating myocardial infarction and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150121 |
|
| RJ01 | Rejection of invention patent application after publication |